Operating Cash Flow CAGR:28.98%(TTM)
Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
Over longer horizons, Operating Cash Flow CAGR averages 24.59% over 3 years and -0.20% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash GSK plc generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.
GSK Operating Cash Flow CAGR Chart
GSK plc (GSK)
GSK Quarterly Operating Cash Flow Growth (YoY)
Operating Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
GSK Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $8.20B | $9.61B | +$1.41B | +17.21% | +17.21% |
| 2024 | $10.04B | $8.20B | $-1.84B | -18.33% | -18.33% |
| 2023 | $9.86B | $10.04B | +$177.23M | +1.80% | +1.80% |
| 2022 | $10.76B | $9.86B | $-898.30M | -8.35% | -8.35% |
| 2021 | $11.53B | $10.76B | $-766.23M | -6.65% | -6.65% |
| 2020 | $10.63B | $11.53B | +$900.45M | +8.47% | +8.47% |
| 2019 | $10.73B | $10.63B | $-100.94M | -0.94% | -0.94% |
| 2018 | $9.34B | $10.73B | +$1.39B | +14.84% | +14.84% |
| 2017 | $8.01B | $9.34B | +$1.33B | +16.62% | +16.62% |
| 2016 | $3.78B | $8.01B | +$4.23B | +111.65% | +111.65% |
| 2015 | $8.06B | $3.78B | $-4.28B | -53.05% | -53.05% |
| 2014 | $11.97B | $8.06B | $-3.91B | -32.64% | -32.64% |
| 2013 | $7.11B | $11.97B | +$4.85B | +68.21% | +68.21% |
| 2012 | $9.72B | $7.11B | $-2.60B | -26.77% | -26.77% |
| 2011 | $10.60B | $9.72B | $-884.39M | -8.34% | -8.34% |
| 2010 | $12.67B | $10.60B | $-2.07B | -16.36% | -16.36% |
| 2009 | $10.63B | $12.67B | +$2.04B | +19.21% | +19.21% |
| 2008 | $11.50B | $10.63B | $-864.18M | -7.52% | -7.52% |
| 2007 | $7.75B | $11.50B | +$3.75B | +48.34% | +48.34% |
| 2006 | $9.61B | $7.75B | $-1.86B | -19.37% | -19.37% |
| 2005 | $9.13B | $9.61B | +$478.78M | +5.24% | +5.24% |
| 2004 | $8.65B | $9.13B | +$478.38M | +5.53% | +5.53% |
| 2003 | $4.93B | $8.65B | +$3.73B | +75.66% | +75.66% |
| 2002 | $6.70B | $4.93B | $-1.78B | -26.51% | -26.51% |
| 2001 | $2.77B | $6.70B | +$3.94B | +142.42% | +142.42% |
| 2000 | $823.55M | $2.77B | +$1.94B | +235.81% | +235.81% |
| 1999 | $681.99M | $823.55M | +$141.55M | +20.76% | +20.76% |
| 1998 | $1.02B | $681.99M | $-334.23M | -32.89% | -32.89% |
| 1997 | $1.45B | $1.02B | $-437.77M | -30.11% | -30.11% |
Quarterly Operating Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $1.51B | -45.0% | +2.0% |
| Q4 2025 | $2.74B | -32.7% | -6.0% |
| Q3 2025 | $4.07B | +41.4% | +41.3% |
| Q2 2025 | $2.88B | +94.6% | +104.5% |
| Q1 2025 | $1.48B | -49.2% | -1.5% |
| Q4 2024 | $2.91B | +1.2% | -36.7% |
| Q3 2024 | $2.88B | +104.7% | +6.7% |
| Q2 2024 | $1.41B | -6.3% | -15.2% |
| Q1 2024 | $1.50B | -67.4% | — |
| Q4 2023 | $4.60B | +70.6% | +117.7% |
| Q3 2023 | $2.70B | +62.7% | +66.8% |
| Q2 2023 | $1.66B | — | -16.7% |
| Q1 2023 | $65.34M | -96.9% | -98.0% |
| Q4 2022 | $2.11B | +30.7% | -66.8% |
| Q3 2022 | $1.62B | -18.7% | -65.7% |
| Q2 2022 | $1.99B | -40.4% | +6.7% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About GSK plc
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels